Quarterly report [Sections 13 or 15(d)]

STOCKHOLDERS' EQUITY (Details)

v3.25.3
STOCKHOLDERS' EQUITY (Details)
 9 Months Ended
Jul. 02, 2025
USD ($)
$ / shares
shares
Jun. 24, 2025
Jun. 23, 2025
Jun. 18, 2025
Jun. 06, 2025
USD ($)
$ / shares
shares
Jul. 21, 2024
USD ($)
D
$ / shares
shares
Sep. 08, 2023
shares
Sep. 30, 2025
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
shares
Jul. 31, 2024
shares
STOCKHOLDERS' EQUITY                      
Reverse stock split ratio   0.033   0.033              
Warrants issued to purchase shares               1,984,808      
Net proceeds from warrant exercises | $               $ 2,251,380 $ 61,410,815    
Proceeds from exercise of warrants | $               $ 3      
Preferred stock, share outstanding               35.6   35.60  
Warrant liability | $               $ 801,650   $ 1,718,000  
Public offering                      
STOCKHOLDERS' EQUITY                      
Gross proceeds from stockholders' equity | $ $ 6,900,000                    
October 2022 Public Offering and Private Placement                      
STOCKHOLDERS' EQUITY                      
Warrants issued to purchase shares               123,609      
Exercise price of warrants (in dollars per share) | $ / shares               $ 58.8      
Minimum                      
STOCKHOLDERS' EQUITY                      
Reverse stock split ratio     0.10                
Maximum                      
STOCKHOLDERS' EQUITY                      
Reverse stock split ratio     0.033                
Class A Units | Public offering                      
STOCKHOLDERS' EQUITY                      
Number of units issued 1,045,000                    
Number of shares in a unit 1                    
Price per unit | $ / shares $ 5                    
Class A Units | Over allotment option                      
STOCKHOLDERS' EQUITY                      
Number of units issued 180,000                    
Class B Unit | Public offering                      
STOCKHOLDERS' EQUITY                      
Number of units issued 335,000                    
Price per unit | $ / shares $ 4.99999                    
Series E-1 preferred stock | September 2023 Private Placement                      
STOCKHOLDERS' EQUITY                      
Shares issued             1,225        
Series E-2 Preferred Stock | September 2023 Private Placement                      
STOCKHOLDERS' EQUITY                      
Preferred stock, share outstanding               35.6      
Common warrant | Public offering                      
STOCKHOLDERS' EQUITY                      
Warrants term 5 years                    
Exercise price of warrants (in dollars per share) | $ / shares $ 5.25                    
Common warrant | Class A Units | Public offering                      
STOCKHOLDERS' EQUITY                      
Number of warrants in a unit 1                    
Number of share of common stock per warrant 1                    
Common warrant | Class B Unit | Public offering                      
STOCKHOLDERS' EQUITY                      
Number of warrants in a unit 1                    
Prefunded Warrant | Class B Unit | Public offering                      
STOCKHOLDERS' EQUITY                      
Number of warrants in a unit 1                    
Number of share of common stock per warrant 1                    
Existing Warrant                      
STOCKHOLDERS' EQUITY                      
Warrants issued to purchase shares         276,044            
Exercise price of warrants (in dollars per share) | $ / shares         $ 9.123            
Proceeds from exercise of warrants | $         $ 2,500,000            
2023 Tranche A Preferred Warrants | Series E-3 preferred stock | September 2023 Private Placement                      
STOCKHOLDERS' EQUITY                      
Warrants issued to purchase shares             2,205        
2023 Tranche B Preferred Warrants                      
STOCKHOLDERS' EQUITY                      
Warrants issued to purchase shares               14,652     14,652
Exercise price of warrants (in dollars per share) | $ / shares               $ 143.25      
Warrants outstanding                     105
2023 Tranche B Preferred Warrants | Series E-4 preferred stock                      
STOCKHOLDERS' EQUITY                      
Warrants issued to purchase shares           1,610          
Preferred stock, par value (in dollars per share) | $ / shares           $ 0.00001          
Number of shares issuable upon conversion of preferred stock           224,663          
Conversion price per share | $ / shares           $ 75.6          
Net proceeds from warrant exercises | $           $ 17,500,000          
Proceeds from exercise of warrants | $           $ 19,400,000          
2023 Tranche B Preferred Warrants | Series E-4 preferred stock | September 2023 Private Placement                      
STOCKHOLDERS' EQUITY                      
Warrants issued to purchase shares             1,715        
2024 Tranche A Warrants                      
STOCKHOLDERS' EQUITY                      
Warrants issued to purchase shares               158,728      
Exercise price of warrants (in dollars per share) | $ / shares           $ 75.6   $ 75.6      
Number of Days following the Announcement of Prescription Drug Use Fee Act Goal By FDA | D           10          
2024 Tranche B Warrants                      
STOCKHOLDERS' EQUITY                      
Warrants issued to purchase shares               149,107      
Exercise price of warrants (in dollars per share) | $ / shares           $ 120   $ 120      
Number of days following the date of the Company's public announcement of its receipt of written approval from the FDA | D           10          
2024 Tranche C Warrants                      
STOCKHOLDERS' EQUITY                      
Warrants issued to purchase shares               75,912      
Exercise price of warrants (in dollars per share) | $ / shares           $ 165   $ 165      
Number of days following the announcement of quarterly gross revenue from sales of iopofosine I 131. | D           10          
Threshold amount of quarterly gross revenues trigger for expiry of warrants | $           $ 10,000,000          
2025 Representative Warrants                      
STOCKHOLDERS' EQUITY                      
Warrants term               5 years      
Warrants issued to purchase shares               82,800      
Exercise price of warrants (in dollars per share) | $ / shares               $ 7.75